IthaMaps

Welcome to IthaMaps

IthaMaps is a global epidemiology database of heamoglobinopathies, illustrating published data on a dynamic global to regional map. Country-specific information on haemoglobinopathy-related policies, prevalence, incidence and overall disease burden is given, including relative allele frequencies of specific globin mutations in each country and/or region, dynamically linked to corresponding IthaGenes entries.

IthaMaps content was supported by partnership with the HVP Global Globin 2020 Challenge

Search

Search Country:		OR	Search for:		Show organisations

Healthcare information:
Major haemoglobinopathies:

Mutation search

Select locus:		Select mutation:

More Fewer search options

General information for Singapore

Singapore

Continent:	Asia
Capital:	Singapore
Population:	4701069
Area (in sq km):	692.7

Haemoglobinopathy-specific healthcare policy information for Singapore

Healthcare policy		Comment/Info	Reference
Prevention programme:	Yes (National)	Based on high-risk population screening. From: Thalassaemia Reports 2012, TIF Pan-Asian Conference.
Prenatal screening:	Yes (National)		[PMID: 27040959]
Antenatal screening:	Yes (National)	Since 1990.
Haemoglobinopathies patient registry:	Yes (National)	National Thalassaemia Registry since 1992.	[PMID: 31213746]
Rare disease patient registry:	No	National Registry of Disease Act does not include rare diseases. From: www.nrdo.gov.sg/
Dedicated treatment centres:	Yes (Regional)
Blood transfusion availability:	Yes (National)		[PMID: 27040959]
Iron chelation availability:	Yes (National)	Iron chelators (DFO, DFP, DFX), and combination DFO and DFP are available, free for thalassaemia patients.	[PMID: 27040959]
MRI facilities:	Yes (National)	From: TIF report on South East Asian Nations, Aug. 2013.
Patient associations:	Yes (National)	E.g.: Thalassaemia Society - Singapore.
Genetic counselling:	Yes (National)	As part of the prevention programme.

Prevalence and incidence of major haemoglobinopathies in Singapore

Haemoglobinopathy		Comment/Info	Reference
Prevalence of β-thalassaemia carriers:	3 % of the population		[PMID: 27040959]
Prevalence of α-thalassaemia carriers:	4 % of the population	TIF report on South East Asian Nations, Aug. 2013
Prevalence of Hb E carriers:	0.64 % of the population		[PMID: 27040959]
Expected incidence of β-thalassaemia:	13 expected affected births/year		[PMID: 24672827]
Known β-thalassaemia patients:	154 patients		[PMID: 24672827]

Global Burden of Disease data for Singapore

Migration data for Singapore

Mutation frequencies in Singapore

Overview (most frequent mutations with their observed average values and range)

β-locus

CD 41/42 (-CTTT): 37.3 %	IVS II-654 C>T: 25.4 %
CD 17 AAG>TAG [Lys>STOP]: 8.95 %	IVS I-5 (G>C): 8.95 %

Detailed mutation frequencies

	Entry ID	Locus	Region	Ethnic Group	Population Type	Sample Size	Study period (from)	Study period (to)	Reference	Comments
	22820	β-locus	Country-wide	Multi-ethnic	Carriers and Patients	134		1994	7927334	Frequencies are shown for beta-globin gene mutations from both carriers and patients. Study samples were acquired from hospitals in Singapore and were of Chinese (mainly), Malay and Indian origin.

Organisations in Singapore

Organisations in Singapore are currently not available

Microattributions

No microattibutions were provided for Singapore. Please contact us, if you are willing to review existing information or provide new data.

To provide new epidemiological information and/or report mistakes, please register/log in first or use the Contact Us form.

Important Note: The relative allele frequencies presented in IthaMaps are not calculated by ITHANET, but they are extracted from the corresponding publications. ITHANET is not responsible for any mistakes in the data. Please use this information with caution! We encourage scientists that have more detailed or updated epidemiological information to contact us.

Disclaimer: The information on this website is provided as an information resource only and must not to be used as a substitute for professional diagnosis and treatment. The ITHANET Portal and IthaMaps are not responsible or liable for any advice, course of treatment, diagnosis or any other information, services or products that an individual obtains through this website.

Note: The information you provide for the specific country will appear on the IthaMaps website and your contribution will be acknowledged.

Country:

Contributor's details

To be included in ITHANET Organisations & Experts

Name:		Organisation's name:
Surname:		Organisation's brief description:
Title:		Organisation's address:
Expertise/Research interests:		Organisation's City:
Address:		Organisation's Country:
City:		Organisation's website:
Country:		E-mail:
ORCID

Healthcare Policies

Health-policy	Select one Answer	Comment
Prevention programme
SCD newborn screening
Prenatal screening
Antenatal screening
Haemoglobinopathies patient registry
Rare disease patient registry
Dedicated treatment centres
Blood transfusion availability
Iron chelation availability
MRI facilities
Patient associations
Genetic counselling

Status of major Haemoglobinopathies

In Expected Incidence of β-thalassaemia and sickle cell disease please provide the number of expected affected births/year (without prevention).
In Incidence of β-thalassaemia and sickle cell disease please provide the number of affected births/year (after prevention).

Haemoglobinopathy	Provide value		Comment
Prevalence of β-thalassaemia carriers		% of the population
Prevalence of sickle cell disease carriers		% of the population
Prevalence of α-thalassaemia carriers		% of the population
Prevalence of Hb E carriers		% of the population
Prevalence of Hb C carriers		% of the population
Expected incidence of β-thalassaemia		expected affected births/year
Expected incidence of sickle cell disease		expected affected births/year
Expected incidence of α-thalassaemia		expected affected births/year
Incidence of β-thalassaemia		affected births/year
Incidence of sickle cell disease		affected births/year
Incidence of α-thalassaemia		affected births/year
Known β-thalassaemia patients		patients
Known sickle cell disease patients		patients

Mutation Frequencies

Please provide details about publications reporting mutation frequencies in the country of reference (either country-wide studies or region-specific studies).

Show on map:		Information to display:
Minimum sample size: